| Matthew Ruder, | |
|
1 University Of New Mexico, Albuquerque, NM 87131-0001 | |
| (505) 272-2610 | |
| (505) 272-1300 |
| Full Name | Matthew Ruder |
|---|---|
| Gender | Male |
| Speciality | Certified Registered Nurse Anesthetist (crna) |
| Experience | 17 Years |
| Location | 1 University Of New Mexico, Albuquerque, New Mexico |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1306014642 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 367500000X | Nurse Anesthetist, Certified Registered | R63624 (New Mexico) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| North Colorado Medical Center | Greeley, CO | Hospital |
| Banner Fort Collins Medical Center | Fort collins, CO | Hospital |
| Mckee Medical Center | Loveland, CO | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Rocky Mountain State Anesthesia Providers | 8729349444 | 49 |
News Archive
Abraxis BioScience, Inc. announced today that findings from a phase 1 randomized trial demonstrated that the nanoparticle albumin bound (nab®) driven chemotherapy, nab-paclitaxel (ABRAXANE® for Injectable Suspension; paclitaxel albumin protein-bound particles for injectable suspension) is well-tolerated and active in the second-line treatment of high-grade, non-muscle-invasive bladder cancer that has been refractory to standard intra-bladder infusion (intravesical) therapy.
The publication of the new joint ESC/ESA Guidelines on non-cardiac surgery: cardiovascular assessment and management introduces a number of recommendations in the field. Among other topics, the Guidelines include updated information on the use of clinical indices and biomarkers in risk assessment, and the use of novel anticoagulants, statins, aspirin and beta-blockers in risk mitigation.
Reuters reports that a new study has found "cancer researchers who design clinical trials, analyze or interpret the data, or play other key scientific roles are four times more likely to have financial ties to industry than their counterparts who have lesser roles in these studies, such as recruiting study subjects or collecting the data."
A growing number of drug-resistant strains of HIV are a threat to the effectiveness of current treatments despite anti-HIV drug cocktails decreasing the number of HIV-related deaths and improving the quality of life for HIV patients.
A recent study published on the preprint server medRxiv in October 2020 reports a new diagnostic test for SARS-CoV-2 based on the detection of antibodies.
› Verified 1 days ago
| Entity Name | Rocky Mountain State Anesthesia Providers |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1730692054 PECOS PAC ID: 8729349444 Enrollment ID: O20180220003107 |
News Archive
Abraxis BioScience, Inc. announced today that findings from a phase 1 randomized trial demonstrated that the nanoparticle albumin bound (nab®) driven chemotherapy, nab-paclitaxel (ABRAXANE® for Injectable Suspension; paclitaxel albumin protein-bound particles for injectable suspension) is well-tolerated and active in the second-line treatment of high-grade, non-muscle-invasive bladder cancer that has been refractory to standard intra-bladder infusion (intravesical) therapy.
The publication of the new joint ESC/ESA Guidelines on non-cardiac surgery: cardiovascular assessment and management introduces a number of recommendations in the field. Among other topics, the Guidelines include updated information on the use of clinical indices and biomarkers in risk assessment, and the use of novel anticoagulants, statins, aspirin and beta-blockers in risk mitigation.
Reuters reports that a new study has found "cancer researchers who design clinical trials, analyze or interpret the data, or play other key scientific roles are four times more likely to have financial ties to industry than their counterparts who have lesser roles in these studies, such as recruiting study subjects or collecting the data."
A growing number of drug-resistant strains of HIV are a threat to the effectiveness of current treatments despite anti-HIV drug cocktails decreasing the number of HIV-related deaths and improving the quality of life for HIV patients.
A recent study published on the preprint server medRxiv in October 2020 reports a new diagnostic test for SARS-CoV-2 based on the detection of antibodies.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Matthew Ruder, 933 Bradbury Dr Se, Suite 2222, Albuquerque, NM 87106-4374 Ph: (505) 272-3120 | Matthew Ruder, 1 University Of New Mexico, Albuquerque, NM 87131-0001 Ph: (505) 272-2610 |
News Archive
Abraxis BioScience, Inc. announced today that findings from a phase 1 randomized trial demonstrated that the nanoparticle albumin bound (nab®) driven chemotherapy, nab-paclitaxel (ABRAXANE® for Injectable Suspension; paclitaxel albumin protein-bound particles for injectable suspension) is well-tolerated and active in the second-line treatment of high-grade, non-muscle-invasive bladder cancer that has been refractory to standard intra-bladder infusion (intravesical) therapy.
The publication of the new joint ESC/ESA Guidelines on non-cardiac surgery: cardiovascular assessment and management introduces a number of recommendations in the field. Among other topics, the Guidelines include updated information on the use of clinical indices and biomarkers in risk assessment, and the use of novel anticoagulants, statins, aspirin and beta-blockers in risk mitigation.
Reuters reports that a new study has found "cancer researchers who design clinical trials, analyze or interpret the data, or play other key scientific roles are four times more likely to have financial ties to industry than their counterparts who have lesser roles in these studies, such as recruiting study subjects or collecting the data."
A growing number of drug-resistant strains of HIV are a threat to the effectiveness of current treatments despite anti-HIV drug cocktails decreasing the number of HIV-related deaths and improving the quality of life for HIV patients.
A recent study published on the preprint server medRxiv in October 2020 reports a new diagnostic test for SARS-CoV-2 based on the detection of antibodies.
› Verified 1 days ago
Francis Joseph Stoecker Iii, CRNA Nurse Anesthetist - CR Medicare: Medicare Enrolled Practice Location: 1313 Dakota St Se, Albuquerque, NM 87108 Phone: 719-351-7921 | |
Kyle Rodgers, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 6709 Academy Rd Ne Ste A, Albuquerque, NM 87109 Phone: 505-308-3145 | |
Mr. J D Sharick, CRNA Nurse Anesthetist - CR Medicare: Not Enrolled in Medicare Practice Location: 2211 Lomas Blvd Ne, Albuquerque, NM 87106 Phone: 505-272-3119 | |
Hideyo Tsumura, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 4401 Masthead St Ne Ste 120, Albuquerque, NM 87109 Phone: 505-243-7729 Fax: 505-243-4804 | |
Mr. Michael Bailey, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 7788 Jefferson St Ne, Albuquerque, NM 87109 Phone: 505-999-1600 Fax: 505-999-1650 | |
David Vincent Dick, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 1100 Central Ave Se, Albuquerque, NM 87106 Phone: 505-841-1234 Fax: 505-841-1956 | |
Morgan J Ouellette Morrow, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 1100 Central Ave Se, Albuquerque, NM 87106 Phone: 505-841-1234 Fax: 505-841-1956 |